Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Key Findings from the monarchE Trial

July 6th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.

Adjuvant Therapy Options in HER2+ eBC and Clinical Data on the PH Regimen

July 6th 2023

Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.

Treating HER2+ Breast Cancer with CNS Involvement

July 6th 2023

Clinical insights on approaches to treating HER2+ metastatic breast cancer with central nervous system involvement.

Endocrine Therapy for Early-Stage Breast Cancer

July 6th 2023

Expert medical oncologists provide an overview of current endocrine therapy approved for early-stage breast cancer.

How Does Response to Neoadjuvant Therapy Affect Prognosis and Inform Adjuvant Selection?

July 6th 2023

Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.

Updates from ASCO 2023 in HER2+ Metastatic Breast Cancer

July 6th 2023

Megan Kruse, MD, reviews clinical trial data updates from the 2023 ASCO Annual Meeting on HER2+ metastatic breast cancer.

Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer

July 5th 2023

Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.

Factors Informing the Selection and Use of OFS in Breast Cancer

July 5th 2023

Expert perspectives on the appropriate selection and use of OFS in premenopausal patients with breast cancer.

Data From the SOFT and TEXT Trials: Combination Therapy With OFS in Breast Cancer

July 5th 2023

Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the SOFT and TEXT clinical trials to elucidate combination treatment strategies with ovarian function suppression (OFS).

Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer

July 4th 2023

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer

July 4th 2023

The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.

Pelareorep Plus Paclitaxel Induces Responses in Metastatic HR+/HER2– Breast Cancer

July 3rd 2023

The combination of the oncolytic reovirus pelareorep and paclitaxel generated responses in patients with metastatic hormone receptor–positive/HER2-negative breast cancer.

Dr Coopey on the Benefits of Axillary Surgery Omission or De-Escalation in Breast Cancer

June 29th 2023

Suzanne B. Coopey, MD, FACS, discusses the benefits seen with the de-escalation of axillary lymph node surgery for patients with breast cancer, as well as current recommendations for the de-escalation or omission of this procedure.

Risk Factors and the Treatment Plan

June 29th 2023

Rachel Layman, MD, describes her impression of the case and discusses risk assessment and a treatment plan for the patient.

Clinical Case 1: High-Risk Early-Stage HR+ Breast Cancer

June 29th 2023

Stephanie Graff, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Data Updates from SABCS 2022 in HER2+ Metastatic Breast Cancer

June 29th 2023

An expert on HER2+ metastatic breast cancer reviews data from the DESTINY-Breast02 and DESTINY-Breast03 trials, which were updated at the 2022 San Antonio Breast Cancer Symposium.

Neoadjuvant Systemic Therapy for HER2+ eBC: Clinical Considerations and Evolving Modalities

June 29th 2023

Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.

Evolving Treatment Strategies for HER2+ Metastatic Breast Cancer

June 29th 2023

Megan Kruse, MD, discusses the evolving treatment landscape for patients with HER2+ metastatic breast cancer.

HER2+ Early Breast Cancer: Treatment Optimization and Review of Standard-of-Care Neoadjuvant Regimens

June 29th 2023

Heather McArthur, MD, and Debu Tripathy, MD, lead a discussion on risk stratification and optimizing treatment for HER2+ early breast cancer (eBC), followed by a review of standard-of-care systemic therapy regimens in the preoperative/neoadjuvant setting.

Fertility Preservation in Breast Cancer: Use of GnRH Agonists

June 28th 2023

Comprehensive insight to available gonadotropin-releasing hormone (GnRH) agonists in breast cancer and the role they play when thinking about fertility preservation.